News >

Ruxolitinib Retains Benefit in Polycythemia Vera With Longer Follow-Up

Published: Wednesday, Dec 20, 2017

blood cellsResponses to ruxolitinib (Jakafi) in patients with polycythemia vera (PV) were maintained by a majority of primary responders at 4 years’ follow-up, according to an updated analysis of the RESPONSE trial presented at the 2017 ASH Annual meeting.1

Two on-treatment deaths occurred in the ruxolitinib arm since the week-80 analysis (gastric cancer and unspecified malignant neoplasm, neither considered related to treatment). Additionally, 4 on-treatment fatal AEs occurred among patients who crossed over to ruxolitinib, but none were considered related to treatment with ruxolitinib.


  1. Kiladjian JJ, Verstovsek S, Griesshammer M, et al. Results from the 208-week (4-Year) follow-up of RESPONSE trial, a phase 3 study comparing ruxolitinib (Rux) with best available therapy (BAT) for the treatment of polycythemia vera (PV). Presented at: 2017 ASH Annual Meeting; December 9-12, 2017; Atlanta, GA. Abstract 322.
  2. Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372(5):426-435. doi: 10.1056/NEJMoa1409002.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication